10-Q: VivoSim Labs Reports Q2 Results, Faces Going Concern Doubt

VivoSim Labs, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, detailing a strategic shift towards services, continued operating losses, and significant liquidity concerns.

Summary

• VivoSim Labs, Inc. has transitioned its business model to focus on providing testing services for drugs and drug candidates using 3D human tissue models, particularly for liver and intestinal toxicology.
• The company reported total revenues of $51,000 for the three months ended September 30, 2026, and $69,000 for the six months ended September 30, 2026.
• Operating expenses remain high, with research and development expenses at $1.1 million and $2.2 million for the three and six-month periods, respectively, and selling, general, and administrative expenses at $2.2 million and $3.9 million.
• The company incurred net losses of $475,000 for the three months and $1,813,000 for the six months ended September 30, 2026.
• A significant event was the $5.0 million milestone payment received in July 2026 related to the prior sale of its FXR program.
• The company has substantial additional funding needs and management has concluded that substantial doubt exists about its ability to continue as a going concern.
• VivoSim Labs is actively seeking additional capital through debt or equity financings.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued operating losses, substantial doubt about the company's ability to continue as a going concern, and significant risks related to future funding and market volatility.

Positives

• The company received a $5.0 million milestone payment in July 2026 related to the sale of its FXR program.
• Service revenue generation has commenced, with $22,000 reported for the three months ended September 30, 2026, indicating progress in the new business model.
• The company's liver toxicology platform demonstrated >90% sensitivity and >95% specificity in scientific presentations, suggesting strong predictive capabilities.
• Cash and cash equivalents increased to $8.6 million as of September 30, 2026, from $5.0 million as of March 31, 2026.
• Working capital improved to $6.7 million as of September 30, 2026, from $3.8 million as of March 31, 2026.

Negatives

• The company incurred net losses of $475,000 for the three months and $1,813,000 for the six months ended September 30, 2026.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern.
• Operating expenses, particularly in R&D and SG&A, continue to significantly outweigh revenues.
• The company has a history of operating losses and expects to incur significant additional operating losses.
• The company's common stock is at risk of delisting from the Nasdaq Capital Market due to not meeting the minimum bid price requirement.
• The company's ability to raise substantial additional funding is critical and uncertain.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern, requiring significant additional funding.
• The company's business model, focused on 3D human tissue models for drug testing, is new and unproven and may not be accepted by partners or regulators.
• Intense competition exists in the biotechnology and pharmaceutical services sector from larger, well-resourced entities.
• Reliance on a limited number of key customers for service revenue could adversely affect results if a customer is lost or reduces project scope.
• Dependence on Viscient Biosciences, Inc. for certain commercial services poses a risk if Viscient fails to perform or if the technology transfer is delayed.
• The company's testing services may not perform as expected, contain errors, or not be accepted by customers or regulators, leading to reputational harm and liability claims.
• The company requires a constant, steady, and reliable supply of human cells, and any disruption or cost increase could harm the business.
• The company may not be able to maintain the listing of its common stock on the Nasdaq Capital Market, which could harm liquidity and the ability to raise capital.

Future Outlook

The company anticipates accelerated adoption of human tissue models following FDA guidance and plans to grow its service revenue. However, it requires substantial additional funding to support future operating activities and cannot guarantee future financing will be available on favorable terms.

Management Comments

• Management has concluded that the prevailing conditions and ongoing liquidity risks faced by the Company raise substantial doubt about its ability to continue as a going concern for at least one year following the date these condensed consolidated financial statements are issued.
• The Company will need to raise additional capital to implement this business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises.
• Going forward, our main focus is to grow service revenue, and we expect service revenue to increase in the coming quarters.
• As we grow service revenue and improve efficiencies, we expect our gross margins to improve and cost of services provided to increase at a slower pace relative to increases in service revenue.

Industry Context

StockSavvy.ai notes that VivoSim Labs is operating in the growing field of New Approach Methodologies (NAMs) for drug testing, driven by regulatory shifts away from animal testing. However, the company faces significant challenges in commercializing its services and demonstrating profitability in a competitive landscape.

Comparison to Industry Standards

• The company's reported liver toxicology platform sensitivity of >90% and specificity of >95% is presented as 'world's best' by the company, suggesting a potentially high standard in predictive toxicology.
• The shift towards NAMs for drug testing is a broader industry trend, with companies like Eurofins Scientific and SGS offering similar services, though VivoSim aims to differentiate with its specific 3D tissue models.
• The company's focus on reducing the risk and cost of drug development aligns with industry pressures to improve efficiency and success rates, where less than 10% of drug candidates entering clinical trials are approved.

Legal Proceedings

• H.C. Wainwright & Co., LLC filed a complaint alleging breach of a tail financing provision, seeking damages and attorneys fees. The company filed counterclaims, but they were dismissed. The company is defending against H.C. Wainwright's claims.

Related Party Transactions

• VivoSim Labs has entered into agreements with Viscient Biosciences, Inc., where Keith Murphy (VivoSim's Executive Chairman) is CEO. Viscient provides R&D consulting and commercial services to VivoSim. VivoSim also licenses technology from Viscient.
• Certain board members of VivoSim are investors in Viscient.

Stakeholder Impact

• Existing stockholders face significant dilution risk from future equity financings and potential volatility in stock price.
• Creditors and suppliers may face uncertainty regarding the company's ability to continue as a going concern and meet its obligations.
• Employees may face job security concerns due to the company's financial precariousness and need for future funding.
• Customers may be impacted if the company's services are disrupted due to financial difficulties or if Viscient fails to perform critical services.

Next Steps

• Focus on growing service revenue and improving gross margins.
• Seek substantial additional funding through debt or equity financings.
• Continue to develop and refine 3D human tissue models for drug testing.
• Complete technology transfer of the NAMKind Liver Model platform from Viscient.
• Manage ongoing legal proceedings and risk factors.

Key Dates

Recommendation

The company's significant operating losses, substantial doubt about its ability to continue as a going concern, and high reliance on future uncertain financing make it a highly speculative investment. The risk of delisting from Nasdaq further exacerbates these concerns. While the shift to a services model and the potential of NAMs are positive, the immediate financial health and execution risks outweigh these potential benefits for a seasoned investor.

Keywords

3D human tissue models, drug toxicology testing, pharmaceutical services, biotechnology, liver toxicology, intestinal toxicology, new approach methodologies, going concern